- Home
- Publications
- Publication Search
- Publication Details
Title
The molecular basis for current targets of NASH therapies
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 29, Issue 2, Pages 151-161
Publisher
Informa UK Limited
Online
2019-12-18
DOI
10.1080/13543784.2020.1703949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
- (2019) A.J. Scheen DIABETES & METABOLISM
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum
- (2019) Amanda Cheung et al. HEPATOLOGY
- Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
- (2019) Soumik BasuRay et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuropeptides at the crossroad of fear and hunger: a special focus on neuropeptide Y
- (2019) Lucas B. Comeras et al. Annals of the New York Academy of Sciences
- Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target?
- (2019) Antonio Romero et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease
- (2019) Stephen A. Hoang et al. Scientific Reports
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- The role of PNPLA3 in health and disease
- (2018) Piero Pingitore et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-stage Liver Disease Scores Compared With Placebo
- (2018) Catherine T. Frenette et al. Clinical Gastroenterology and Hepatology
- Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
- (2018) Fernando Bril et al. Clinical Gastroenterology and Hepatology
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Farnesoid X receptor modulators 2014-present: a patent review
- (2018) Valentina Sepe et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis
- (2018) Giovanni Musso et al. GASTROENTEROLOGY
- Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy
- (2018) Daniel J. Firl et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Pharmacotherapy for NASH: Current and emerging
- (2018) Monica A. Konerman et al. JOURNAL OF HEPATOLOGY
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity — A randomized trial
- (2018) Nathan C. Winn et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
- (2018) Mario Masarone et al. Oxidative Medicine and Cellular Longevity
- Role of Human Brown Fat in Obesity, Metabolism and Cardiovascular Disease: Strategies to Turn Up the Heat
- (2018) Jonatan R. Ruiz et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Metabolic and Bariatric Surgery: An Effective Treatment Option for Obesity and Cardiovascular Disease
- (2018) Wayne J. English et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects
- (2018) KEC Bouter et al. Clinical and Translational Gastroenterology
- ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
- (2018) Ju Youn Kim et al. CELL
- Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
- (2018) Samer Al-Dury et al. Frontiers in Pharmacology
- Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
- (2018) Mitchell Shiffman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New Advances in Adaptive Thermogenesis: UCP1 and Beyond
- (2018) Edward T. Chouchani et al. Cell Metabolism
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Serotonin signals through a gut-liver axis to regulate hepatic steatosis
- (2018) Wonsuk Choi et al. Nature Communications
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study
- (2017) Kathryn Stiede et al. HEPATOLOGY
- Treatment of NAFLD with diet, physical activity and exercise
- (2017) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice
- (2017) Bérengère Benoit et al. NATURE MEDICINE
- NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD
- (2017) Jake P. Mann et al. Nature Reviews Gastroenterology & Hepatology
- Mechanisms of hepatic stellate cell activation
- (2017) Takuma Tsuchida et al. Nature Reviews Gastroenterology & Hepatology
- Brown adipose tissue detected by PET/CT imaging is associated with less central obesity
- (2017) Aileen L. Green et al. NUCLEAR MEDICINE COMMUNICATIONS
- Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms
- (2017) Frank W. Booth et al. PHYSIOLOGICAL REVIEWS
- Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
- (2017) Robert E. Steinert et al. PHYSIOLOGICAL REVIEWS
- Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
- (2017) Stephen L. Pinkosky et al. TRENDS IN MOLECULAR MEDICINE
- Clinical relevance of the bile acid receptor TGR5 in metabolism
- (2017) F Samuel van Nierop et al. Lancet Diabetes & Endocrinology
- Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
- (2016) Lucas D. BonDurant et al. Annual Review of Nutrition
- Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
- (2016) Timothy Hardy et al. Annual Review of Pathology-Mechanisms of Disease
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
- (2016) Sahil Mittal et al. Clinical Gastroenterology and Hepatology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores
- (2016) Jeffrey B. Schwimmer et al. GASTROENTEROLOGY
- Pathogenesis of Nonalcoholic Steatohepatitis
- (2016) Mariana Verdelho Machado et al. GASTROENTEROLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
- (2016) Fabio Piscaglia et al. HEPATOLOGY
- Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
- (2016) Petra Hirsova et al. JOURNAL OF LIPID RESEARCH
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- (2016) Manoela Mota et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Central nervous system regulation of eating: Insights from human brain imaging
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
- (2016) Giovanni Musso et al. NATURE REVIEWS DRUG DISCOVERY
- Neurotrophic factor control of satiety and body weight
- (2016) Baoji Xu et al. NATURE REVIEWS NEUROSCIENCE
- Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health Implications
- (2016) Xin Gen Lei et al. PHYSIOLOGICAL REVIEWS
- Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials
- (2016) Shira Zelber-Sagi et al. Therapeutic Advances in Gastroenterology
- Turn Up the Heat: Circulating Serotonin Tunes Our Internal Heating System
- (2015) Jochen G. Schneider et al. Cell Metabolism
- Brown and Beige Fat: Molecular Parts of a Thermogenic Machine
- (2015) Paul Cohen et al. DIABETES
- Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
- (2015) S. P. Rajeev et al. DIABETES OBESITY & METABOLISM
- Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
- (2015) Guillaume Lassailly et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Weight regaining: From statistics and behaviors to physiology and metabolism
- (2015) Costas A. Anastasiou et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Inflammasome activation and function in liver disease
- (2015) Gyongyi Szabo et al. Nature Reviews Gastroenterology & Hepatology
- GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
- (2014) D. Beiroa et al. DIABETES
- Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis
- (2014) Wolfgang Stremmel et al. FASEB JOURNAL
- Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
- (2013) Rebecca Taub et al. ATHEROSCLEROSIS
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
- (2013) Jessica Dyson et al. JOURNAL OF HEPATOLOGY
- Pharmacological agents for NASH
- (2013) Vlad Ratziu Nature Reviews Gastroenterology & Hepatology
- Bile acid receptors as targets for drug development
- (2013) Frank G. Schaap et al. Nature Reviews Gastroenterology & Hepatology
- Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study
- (2012) L. Gerber et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
- (2011) Vlad Ratziu et al. HEPATOLOGY
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- (2011) Arun J. Sanyal et al. HEPATOLOGY
- Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease
- (2011) Cynthia D. Guy et al. HEPATOLOGY
- Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
- (2011) Romina Lomonaco et al. HEPATOLOGY
- Lipotoxicity in NASH
- (2011) Michael Fuchs et al. JOURNAL OF HEPATOLOGY
- Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress
- (2011) Ira Tabas et al. NATURE CELL BIOLOGY
- Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
- (2010) Jody Dushay et al. GASTROENTEROLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
- (2009) Manal F. Abdelmalek et al. HEPATOLOGY
- Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis
- (2009) Naim Alkhouri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
- (2008) Adilson Guilherme et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease
- (2008) Eric R Kallwitz et al. WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More